JP3459013B2 - An agent for treating arthritis containing uridine as an active ingredient - Google Patents

Description

Description: TECHNICAL FIELD The present invention relates to a therapeutic agent for the treatment of common sores that contains uridine as an active ingredient. More specifically, the use of uridine, which is a nucleoside, is a novel therapeutic effect for the treatment of common sores and its effects. It is the one that is contained in the garbage. Background Art Uridine is one of the four ribonucleosides necessary for constructing RNA and is distributed in nature in a wide range. Its molecular weight is 244.20 and its molecular formula is C ₉
H ₁₂ N ₂ O ₆ is 10, and its structural formula is as follows. The known pharmacological action of uridine is that when uridine is thrown, it is immediately converted into uridine 5'-phosphate by the catalytic action of uridine quinase enzyme in the body.
Useful for enzyme deficiency or pyrimidine nucleotidite deficiency and nucleic acid synthesis deficiency.
There is a report (MATINDALE, 1989,1627) that was used as a pottery to reduce OTIC ACIDURIA), and it was used as a component of a composite sardine even in the Republic of Korea. Uridine itself is not reported to have any effect on sores. While studying the components used as raw herbs, the present researcher screened various substances that were separated and purified as a single ingredient,
It was found that one of the components isolated from the plant had an excellent therapeutic effect on scabitis, the molecular structure of the substance was revealed, and as a result, it was confirmed that it was uridine and the present study was completed. ． When uridine has been used in medical supplies, it is used as a compound iron with other drugs to treat vascular disease, hepatointestinal protection,
It is known to be used for peripheral dementia, brachyplasty hypoxia, etc., but its curative effect on arthritis is not known. Disclosure disclosure The purpose of this disclosure is to formula The present invention provides a swelling-improving syrup containing uridine as an effective ingredient. A simple explanation of the face. Rake 1 is a graph showing the time course of edema at the swelling site of the swelling of the swelling of the urateru group and the group receiving uridine. This is the best mode for the treatment of glaucoma. This glaucoma has an excellent effect of treating glaucoma when uridine of 0.6-60 mg / kg is provided by providing an improving ingredient of glaucoma containing uridine. ． In the case of poaching the active ingredient thereof, it can be made into a pot-making product such as tablets, porridges, capsules, etc., which can be manufactured according to a commonly used method. In order to produce these shavings, lactose, corn starch, and shaping syrups such as magnesium stearate can be added. The present authors have confirmed that uridine promotes cartilage formation and suppresses bone resorption (BONE RESORPTION), and reduces inflammation of the tissues in the spinal joint, and promotes regeneration by the bone marrow. That is, in order to confirm the therapeutic effect of uridine on scabitis, COLLAGEN-INDUCED ARTHRITIS, which is a model of animal disease of rheumatoid arthritis.
The edema of the swelling part of the arthralitis is faster than that of the sera group, and the extent of the final edema before the sacrifice is significantly different. It was confirmed that the resulting tissue inflammation was reduced and regeneration was promoted. In addition, we believe that uridine is effective in the treatment of other autoimmune diseases, as collagen scabitis is a category of autoimmune diseases. As a result of the toxicity of uridine, uridine was 0.0% in the original rats and mice.
1,0.1,10,100mg / Kg each, and observed for more than 1 week,
I couldn't detect any abnormalities. " Examples Hereafter, the present invention will be explained more concretely by the following examples, but the present invention is not limited thereto. Example 1. Collagen scabitis and its effects (1) Induction and observation of collagen scabitis. Native bovine type II coll (Native bovine type II coll)
agen) was dissolved to 2 mg / ml and mixed with unfinished Proint (Freund) zabuta 1: 1 to prepare an emulsion. 1m of this emulsion on a Lewis rat ridge
8 days later, an emulsion was prepared by the same method, and then 1 ml was intraperitoneally injected. After that, a group of rats with scabitis and a group with uridine (Uridine group 1 10 μg twice a day, Uridine group 2
1 mg each twice a day), and the thickness and height of the foot on which the arthritis was caused were measured at appropriate intervals. Serum was prepared at regular intervals in the veins of the tail to observe the anti-hypertensive changes in collagen type II. (2) Observation of the anti-hypertensive effect of collagen type II on the swelling time Tanatech Immulon 4 p
late) 50μl of each well type collagen type
After adding II solution (10 μg / ml) and coating overnight, 3% BSA-PBS (bovine serum albumin-ph) was added overnight.
Blocking was performed with an osphate buffered saline) solution. The plate was first washed with PBS four times, and the serum obtained from the Lewis rat was added to the plate, which was then reacted overnight. Then, the cells were washed 4 times with PBS, and anti-rat immunoglobulin G (IgG) anti-rat of goat labeled with peroxidase was added. After overnight, washing with PBS four times, and using O-phenylenediamine as a substrate, and then bleaching, ETA plate reading device (ETA plat
The absorbance was measured at 405 nm with an e reader). (3) ³ H-thymidine absorption analysis Spleen cells were obtained by using a mesh with the spleen obtained by sacrificing two groups of rats. Suspended in Dulbecco's modified Igls medium containing 0.5% of the same serum in each well
Put about 2.5x10 ⁶ spleen cells, collagen type II
Was added to 0 μg / ml, 0.01 μg / ml, 0.1 μg / ml, 1 μg / ml, 10 μg / ml. After standing in a CO ₂ incubator for 56 hours, 0.5 μCi of ³ H-thymidine was added. .16 hours later, harvested with an automatic harvester, scintillation counter (scinti
Radioactivity was measured using an llation counter). (4) Histopathological Examination When Lewis rats were sacrificed for ³ H-thymidine uptake analysis, the hindpaw, which suffered from osteoarthritis, were fixed with formalin, and inorganic substances were removed to prepare slides for histopathology. I observed the findings. The result of this study was that after the necrotizing outbreak, Lewis rats fed twice daily with uridine and the group fed with distilled water were treated with glaucoma as indicated by 圖 1. It is recognized that there is a significant difference in the degree and speed at which the edema of the foot in which the swelling occurs occurs. But Tables 1 and 2
As shown in Fig. 4, there was little difference between the two groups in the change in anti-tumor activity and in the ³ H-thymidine absorption of spleen cells.
From histopathological findings, Lewis rats fed with uridine had more hyaline cartilage than the rats fed with distilled water, and the formation of fibrous cartilage was more active. I showed you that. In addition, the findings of inflammation were shown to be different to all extent in the two groups, but the findings of bone resorption were confirmed to be shown only in the group to which distilled water was poured. Example 2 Production of Chinese medicine tablets (1) According to the usual method, a tablet which could not be effective against the effect of uridine was added according to the following composition and mixed to produce tablets. (2) Tablets were produced according to the following composition according to a conventional method.

─────────────────────────────────────────────────── --- Continuation of the front page (56) References JP-A-4-243830 (JP, A) JP-A-2-25425 (JP, A) JP-A 60-136515 (JP, A) JP-A 62- 145019 (JP, A) FOX, R.A. I. , Et al. , TREATMENT OF R HEUMATOID ARTHRITIS (RA) WITH THE PYR IMIDINE SYNTHESIS INHIBITOR TRIACETY L-6-AZAURIDINE, Ar thresholds Rheum. , 1992, 35 (Suppl. 9), p. S203 (58) Fields investigated (Int.Cl. ⁷ , DB name) A61K 31/70-31/713 A61P 1/00-43/00 C07H 19/00-19/067 CA (STN) REGISTRY (STN) WPI (DIALOG)

Claims (2)

(57) [Claims] 1. A therapeutic agent for scabies containing uridine as an effective ingredient. 2. The treatment powder for scabitis according to claim 1, wherein the said syrup is a tablet.